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In spite of the apparent improvement in outcome in locally advanced breast cancer, the prognosis remains dismal in many
patients. The aim of this study was to deﬁne prognostic subgroups within this heterogeneous entity. Between 1990 and 1999,
104 consecutive patients with locally advanced breast cancer were treated by a multimodality programme consisting of 4–6
courses of CAF induction chemotherapy followed by surgery, breast-conserving when feasible. In most cases, chemotherapy
was then resumed, up to a total of eight courses, followed by locoregional radiation therapy. Patients with hormone receptor-
positive tumours received tamoxifen (20 mg day
71) for 5 years. At a median follow-up of 57 months, the 5-year overall
survival for the entire group and the disease-free survival for the 94 operated patients were 65% and 53%, respectively.
Univariate analysis identiﬁed 10 prognostic factors of overall and disease-free survival, of which four retained signiﬁcance on
multivariate analysis: inﬂammatory breast cancer (P=0.0000, P=0.0004, respectively), baseline tumour markers (P=0.003 for
both), post-chemotherapy number of involved nodes (P=0.003; P=0.017) and extracapsular spread (P=0.052; P=0.014). In
conclusion, besides inﬂammatory features, baseline tumour markers and post-chemotherapy nodal status are strong predictors
of outcome in locally advanced breast cancer.
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Locally advanced breast cancer (LABC) accounts for 10–29% of all
breast carcinomas in the Western World (Lippman et al, 1986;
Valero et al, 1996). With the introduction of multimodality thera-
peutic strategies, 5-year disease-free survival rates in the order of
30–70% have been reported, with overall survival ranging between
35 and 80% (Hortobagyi and Buzdar, 1991; Hortobagyi et al,
1996). Overall, distant failure and early death are not uncommon,
emphasizing the need for more effective treatments.
LABC is a heterogeneous group of tumours, ranging from
neglected slow-growing neoplasms to rapidly proliferating and
aggressive ones. Therefore, a uniform treatment approach is
doomed to fail. To better deﬁne patient subgroups and to select
the more appropriate treatment options, intensive efforts have been
invested to identify prognostic factors. Researchers agree that the
presence of inﬂammatory breast cancer (IBC) (Jaiyesimi et al,
1992; Palangie et al, 1994) and poor pathological response to
neoadjuvant chemotherapy (Feldman et al, 1986; Sataloff et al,
1995; Honkoop et al, 1998) yield a worse outcome. Conclusions
regarding other possible factors are conﬂicting.
The present retrospective prognostic factor analysis included a
relatively homogeneous group of 104 patients with LABC treated
in one institution by a uniform policy during a fairly short period
of time.
MATERIALS AND METHODS
Patients
The study sample consisted of 104 consecutive patients with LABC
who were treated at Rabin Medical Center from 1990 to 1999. LABC
was deﬁned as histologically or cytologically documented American
Joint Committee on Cancer (AJCC) (Fleming et al, 1997) stages
IIB, IIIA, IIIB or IV (with ipsilateral supraclavicular lymph node
involvement only) breast cancer. Before the onset of treatment, all
patients underwent a baseline work-up, as follows: complete history
and physical examination, complete blood count, blood chemistry
analysis, serum CEA and CA-15.3 levels, chest X-ray, abdominal
computerized tomography or ultrasonography, bone scan, bilateral
mammography, and cardiac scintigraphy (MUGA).
Treatment programme
On conﬁrmation of the diagnosis, patients were offered a multi-
modality treatment programme consisting of 4–6 courses of
induction chemotherapy followed, when maximal response was
achieved, by surgery. Thereafter, adjuvant chemotherapy was admi-
nistered to an overall total of eight courses followed by locoregional
radiation therapy. Patients with hormone receptor-positive tumours
also received adjuvant tamoxifen (20 mg day
71) for 5 years.
Chemotherapy
Preoperative chemotherapy consisted of cyclophosphamide
600 mg m
72, doxorubicin 60 mg m
72, and 5-ﬂuorouracil
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72 (CAF protocol), all administered as a rapid intrave-
nous infusion on day 1 of each cycle and repeated every 21 days
for up to eight courses, until a maximal clinical response was
achieved. The clinical response was categorized on the basis of
the physical examination: complete – total resolution of the breast
mass and axillary adenopathy; partial – at least a 50% reduction of
the product of the two largest perpendicular dimensions of the
breast mass and axillary adenopathy: minor – 25% – 50% reduc-
tion of the product of the two largest perpendicular dimensions of
the breast mass and axillary adenopathy; stable disease – less than
25% change in the product of the two largest perpendicular dimen-
sions of the breast mass and axillary adenopathy; progressive
disease – more than 25% increase in tumour size. The pathologi-
cal response was deﬁned as complete when there was no
microscopic evidence of residual tumour, or as microscopic (intra-
ductal or invasive) or macroscopic.
After surgery, the CAF protocol was resumed to a total of eight
courses, unless there was disease progression during treatment. In
three patients, other regimens were used postoperatively: experi-
mental high-dose treatment followed by autologous stem cell
support, or four courses of paclitaxel every 3 weeks, or methotrex-
ate instead of doxorubicin because of impaired cardiac function.
Patients underwent a physical examination after each course, and
systemic work-up, including cardiac scintigraphy, at the end of
both preoperative and postoperative chemotherapy.
Surgery
The standard surgical procedure was a modiﬁed radical mastect-
omy. However, when feasible, breast-conserving surgery, either
lumpectomy or quadrantectomy, with axillary lymph node dissec-
tion was performed. The ultimate decision on the type of surgery
was left to the discretion of the treating physician and the patient.
Surgical specimens were analysed for tumour histology, nodal
status, grade, and hormone receptor status.
Radiotherapy
Radiotherapy was used as adjuvant treatment following surgery in
94 patients, or for deﬁnitive treatment of the residual mass in four
patients. Six patients did not receive radiation treatment owing to
the rapid progression of metastatic disease which necessitated
immediate systemic treatment. Radiation therapy to the chest wall
or residual breast tissue was administered by two tangential ﬁelds
using a megavoltage photon beam (6 MV). When breast-conser-
ving surgery was performed, the tumour bed received a radiation
boost with an electron beam (dose speciﬁed to the 90% isodose
line). For supraclavicular and axillary lymph nodes, a direct ﬁeld
was used. The planned total dose to the tumour bed was 60 Gy,
and to all other ﬁelds, 50 Gy. Treatment was delivered with a 6
MV linear accelerator in daily fractions of 2 Gy each, 5 days a
week.
Follow-up
After completing the primary treatment plan, patients were
followed every 3 months for the ﬁrst 2 years, every 6 months in
the next 3 years, and annually thereafter. Follow-up included
physical examination, blood chemistry and evaluation of tumour
markers. Chest X-ray, upper abdominal ultrasonography and
mammography were done yearly. If recurrent disease was
suspected, a complete staging work-up was performed.
Statistical analysis
Overall survival (OS) was deﬁned as the interval between the date
of diagnosis and the date of death/last date known to be alive.
Disease-free survival (DFS) was deﬁned according to the Manual
of the European Organization of Research and Treatment of
Cancer (EORTC Breast Cancer Cooperative Group, 2000) as the
interval between the date of surgery, or in patients with pathologi-
cal complete response, the date on which complete clinical
response was achieved, and the date of ﬁrst evidence of recurrence.
The analysis of OS included all 104 patients, and of DFS, only
those 94 patients who underwent surgery and were thus rendered
free of disease. Both rates were estimated by the Kaplan-Meier
product limit method (Kaplan and Meier, 1958). Three patients
who died of causes other than breast cancer (second malignancy,
myocardial infarction, or bronchial asthma) were considered lost
to follow-up. Comparisons between subgroups according to
patient, tumour and treatment variables were performed with the
log-rank test. Cox proportional hazard regression models (Cox,
1972) were applied for multivariate analysis. Risk ratios and 95%
conﬁdence intervals (CI) were calculated from the model. SPSS
software was used to perform these tests.
RESULTS
Patient and tumour characteristics
The clinical characteristics of the patient population at presentation
are depicted in Table 1. Median age was 50 years (range 29–72
years). Sixty patients (57%) were of Ashkenazi origin, and 49
(48%) had a history of malignancy in ﬁrst degree relatives, the
most common of which was breast cancer (24 patients). Sixty-four
per cent of the tumours were clinically staged as T3, and 23% had
pathological (cutaneous lymphatic tumour emboli) or clinical (red-
brownish diffuse discolouration and oedema of the skin) features
consistent with inﬂammatory carcinoma. About half the patients
presented with axillary lymphadenopathy. Two-thirds of the
tumours were evaluated for grade and hormone receptor expres-
sion. Thirty-six per cent were found to be poorly differentiated,
and 44% of them were hormone-receptor-positive. Thirty-three
patients (32%) had an elevated baseline serum CEA (45n gm l
71)
(median 10.9; range 5.4–128.3 ng ml
71) and/or CA-15.3
(435 U ml
71) (median 48; range, 35.1–268.8 U ml
71) level.
Treatment
Patients received 3–8 courses of neoadjuvant CAF (median, six
courses); 101 patients (97%) received at least four courses. Three
patients did not complete the induction phase because of disease
progression (one patient) or refusal (two patients). The objective
clinical response rate of the entire group was 76%, with 31%
achieving complete clinical response. Accordingly, 94 of the 104
patients (90.4%) underwent surgery. In 40 patients (38%), the
procedure was breast-conserving. Ten patients (9.6%) did not
undergo surgery because of suspected or overt systemic disease
(seven patients), refusal (two patients), or residual unresectable
disease (one patient).
Pathological examination of the primary tumour revealed a
complete pathological response in 12 patients (11.5%); 10 patients
had microscopic invasive disease and one, in situ residual disease.
Out of the 88 patients who underwent axillary lymph node dissec-
tion (median number of nodes examined – 14, range 2–34), 56
(64%) were found to have metastatic nodal involvement (median
number of involved nodes – 2, range 1–21). None of the patients
who achieved a complete pathological response in the breast had
residual axillary lymph node involvement.
Overall and disease-free survival
At a median follow-up of 57 months (range 19–123 months), 55
patients (53%) were alive with no evidence of disease and nine
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(12), 1404–1410patients (9%) were alive with disease. Three patients (3%) died
without any evidence of breast cancer. The cause of death in each
of these patients was second malignancy, bronchial asthma and
myocardial infarction. Thirty-seven patients (35%) died of disease.
The 5- and 10-year OS rates for the entire group of 104 patients
were 65% and 46%, respectively. For patients who achieved
complete pathological response the 5-year OS reached 92%. The
median OS (104 patients) was 88 months.
Out of the 47 patients (45%) with recurrent disease, 46 had
systemic involvement, of whom 12 (11%) had both locoregional
and distant metastases. The 5-year DFS rate for the 94 patients
who underwent surgery was 53%. Median DFS has not been
reached.
Prognostic factors
Univariate analysis The univariate analysis of the pretreatment
clinical prognostic factors is shown in Table 2. Four factors were
found to signiﬁcantly correlate with poorer outcome (OS and
DFS): clinical tumour size larger than 5 cm, inﬂammatory features,
high grade, and elevated levels of baseline markers. Inﬂammatory
carcinoma had the strongest impact, decreasing the estimated
5-year OS from 79 to 27% (Figure 1). Elevated tumour markers
were associated with a decrease in 5-year OS from 76% to 45%
(Figure 2).
The univariate analysis of the treatment-related prognostic
factors are shown in Table 3. Clinical response was found to signif-
icantly predict only DFS, and its practical consequence, that is, the
decision to perform breast-conserving surgery, seemed to be signif-
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Table 1 Clinical characteristics at presentation
No. of Valid
patients % %
Age (years)
550 48 46.1 46.1
550 56 53.9 53.9
Origin
Ashkenazi Jews 60 57.7 57.7
Sephardic Jews 42 40.4 40.4
Arabs 2 1.9 1.9
*Family history
a
Yes 27 26.0 26.2
No 76 73.1 73.8
*Menopausal status
Premenopausal 47 45.2 47.0
Postmenopausal 53 50.1 53.0
Location
b
Lateral 63 60.6 60.6
Medial 41 39.4 39.4
*Clinical T
T2–T3 79 76.0 76.7
T4
c 24 23.1 23.3
*Clinical size (mm)
45 35 33.6 35.7
45 63 60.6 64.3
Clinical nodal status
N0 51 49.0 49.0
N1 40 38.5 38.5
N2, 3 13 12.5 12.5
Stage
IIB 42 40.4 40.4
IIIA 38 36.5 36.5
IIIB 23 22.1 22.1
IV 1 1.0 1.0
Grade
G1–G2 27 26.0 41.5
G3 38 36.5 58.5
Unknown 39 37.5 –
Oestrogen receptor
Positive 46 44.2 66.7
Negative 23 22.1 33.3
Unknown 35 33.7 –
Progesterone receptor
Positive 37 35.6 53.6
Negative 32 30.8 46.4
Unknown 35 33.6 –
*Baseline markers
Elevated
d 33 31.7 32.3
Normal 69 66.3 67.7
*Missing data: family history – one patient; menopausal state – four patients; clinical
T – one patient; clinical size – 6; baseline markers – two.
aFamily history: breast or
ovarian cancer in ﬁrst-degree relatives.
bLateral: outer quadrants; Medial: medial quad-
rants and central region.
cAll T4 cases were inﬂammatory.
dElevated baseline markers:
elevation of at least one marker – CEA45n gm l
71, CA – 15.3435 U ml
71.
Table 2 Survival by pretreatment characteristics: Univariate analysis
OS
a DFS
a
% P value % P value
Age (years)
550 58 55
550 70 0.24 58 0.80
Origin
Ashkenazi Jews 57 55
Sephardic Jews 74 59
Arabs 100 0.23 100 0.82
Family history
Yes 59 42
No 67 0.35 63 0.05
Menopausal status
Premenopausal 55 49
Postmenopausal 74 0.12 61 0.51
Location
b
Lateral 67 58
Medial 61 0.44 54 0.56
Clinical T
T2–T3 75 64
T4
c 29 0.00 22 0.00
Clinical size
45c m 8 6 7 6
45 cm 52 0.001 45 0.002
Clinical nodal status
N0 65 60
N1 67 55
N2, 3 54 0.35 45 0.78
Grade
G1–G2 74 68
G3 50 0.02 35 0.01
Oestrogen receptor
Positive 65 58
Negative 61 0.80 48 0.55
Progesterone receptor
Positive 65 57
Negative 63 0.71 52 0.93
Baseline markers
Elevated
d 45 37
Normal 74 0.002 65 0.01
aOS=overall survival; DFS=disease-free survival.
bLateral: outer quadrants; Medial:
medial quadrants and central region.
cAll T4 cases were inﬂammatory.
dElevated
baseline markers: elevation of at least one marker – CEA45n gm l
71, CA-
15.3435 U ml
71.
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British Journal of Cancer (2002) 87(12), 1404–1410 ã 2002 Cancer Research UKicantly correlated with both OS and DFS. Four pathological
measures of response correlated with a favourable outcome (OS
and DFS): complete pathological response, residual tumour of
3 cm or smaller, fewer than four positive residual lymph nodes,
and absence of extracapsular nodal spread. Meticulous analysis of
the number of residual lymph nodes (data not shown) indicated
the cut-off of four to be the most predictive of outcome: the
presence of four or more metastatic axillary lymph nodes was asso-
ciated with a decrease in 5-year OS from 84 to 49%, and in DFS
from 65 to 38% (Figure 3). Extracapsular spread was also predic-
tive for both of these measures, as illustrated in Figure 4.
Multivariate analysis
Of the various multivariate models of OS and DFS, the one
depicted in Tables 4 and 5 was chosen because of its clinical rele-
vance, high statistical power, and high availability of patients and
events. According to this model, four factors retained statistical
signiﬁcance: two of the clinical factors available at presentation,
namely, inﬂammatory characteristics and baseline tumour markers,
and two of the treatment-associated factors, namely, number of
involved nodes and extracapsular spread. The latter had only
borderline signiﬁcance in the OS model.
DISCUSSION
The clinical characteristics of our patient population with LABC
largely resemble those of previous reports (Fein et al, 1994; Karls-
son et al, 1998), except for the relatively high rate of hormone
receptor-positive tumours (67%). However, this last ﬁgure should
be viewed with caution, as hormone receptors were examined in
only two-thirds of the cases, either because the tumours were
unoperated or complete pathological response was achieved. The
clinical and pathological response rates in our patients to neoadju-
vant CAF chemotherapy are in accordance with other reported
series (DeLena et al, 1978; Lippman et al, 1986). The high overall
clinical objective response rate of 76% allowed for the fact that
43% of the surgical procedures were breast-conserving. The 5-
and 10-year OS for the entire group (65% and 46%), as well as
the median OS (88 months), are within the upper range of other
published studies (Hortobagyi and Buzdar, 1991; Weshler et al,
1990). Whether these ﬁgures are incidental or reﬂect biological
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Figure 1 Disease-free survival (A) and overall survival (B) by presence
of inﬂammatory breast cancer (IBC).
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Figure 2 Disease-free survival (A) and overall survival (B) by baseline
tumour markers.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(12), 1404–1410or treatment-related phenomena, such as a relatively high percen-
tage of hormonal receptor-expressing tumours or a rather strict
treatment frame, is unclear.
Univariate analysis identiﬁed several variables, some pretreatment
and some treatment-related, as prognostic factors for OS and DFS.
On multivariate analysis, only four retained statistical signiﬁcance:
inﬂammatory features, baseline tumour markers, number of
involved nodes, and extracapsular spread of malignant cells.
Inﬂammatory breast cancer is known to have an aggressive clin-
ical course, very often resulting in early recurrence and death
(Pierce et al, 1992; Sanchez-Forgach et al, 1992). Some authors
have argued against the inclusion of patients with IBC in studies
of LABC because of their clearly worse outcome (Karlsson et al,
1998). In our study, too, inﬂammatory changes were associated
with a signiﬁcant decrease in 5-year survival rates from 79 to
27% (P=0.000) (Figure 1). This emphasizes the inadequacy of
current treatment methods to meet the challenge posed by this
entity. It may also justify separating IBC from other types of LABC.
Serum levels of tumour markers correlate with the stage of the
disease in breast cancer (Fujino et al, 1986; Saﬁ et al, 1991).
However, owing to the low sensitivity and speciﬁcity of these tests,
they are usually regarded as useful only for follow-up after primary
therapy, and for monitoring response to treatment of metastatic
disease (van der Linden et al, 1985; Cheung et al, 2000). However,
in the present study, we found that baseline serum CEA and CA-
15.3 levels could predict patient outcome. As illustrated in Figure
2, patients who presented with an elevation of at least one of these
markers at diagnosis had a 5-year survival rate of 45%, whereas the
rate for patients with markers within normal range was 76%
(P=0.002). Indeed, elevated levels of tumour markers were asso-
ciated with a greater than four-fold risk of dying of breast cancer
and a greater than three-fold risk of recurrence. To the best of
our knowledge, this is the ﬁrst report to identify the prognostic
value of standard tumour markers in LABC. Once validated, tests
for baseline tumour markers which are objective, comparable and
easily obtainable, may be incorporated into the primary care algo-
rithm of LABC.
We found that the pathological response, particularly the axillary
status, is the main determinant of both OS and DFS. Moreover, on
multiple Cox regression models, two parameters of axillary involve-
ment were indicative of outcome: the presence of more than three
involved lymph nodes and extracapsular spread. While the prog-
nostic importance of the former has been reported before
(Kuerer et al, 1998; Victor et al, 1999), the impact of the latter
in this context has not yet been fully recognized.
To identify patients with LABC who are at higher risk of
primary treatment failure, we and others (Sanchez-Forgach et
al, 1992; Honkoop et al, 1998) chose OS and DFS as outcome
measures. Using this approach, we distinguished two pretreatment
and two treatment-related prognostic factors. Other investigators
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Table 3 Survival by treatment-related factors; univariate analysis
OS
a DFS
a
% P value % P value
Neoadjuvant CAF (courses)
56( n=29) 61 64
6( n=56) 69 56
46( n=19) 53 0.38 42 0.17
Clinical response
b
CR+PR (n=76) 71 63
MR+SD (n=23) 48 0.08 36 0.03
Pathological residual disease
c
CR+microscopic (n=23) 87 78
Macroscopic (n=69) 59 0.02 48 0.01
Pathological T
43c m ( n=63) 75 63
43c m ( n=21) 43 0.01 38 0.01
Pathological nodal status
d
0–3 (n=48) 79 69
54( n=40) 55 0.002 42 0.005
Extracapsular spread
Yes (n=15) 60 40
No (n=73) 69 0.06 59 0.03
Surgery
Mastectomy (n=54) 51 43
Breast conserving (n=40) 87 0.00 72 0.01
Total CAF
e (courses)
46( n=56) 67 58
46( n=48) 72 0.97 54 0.81
Adjuvant tamoxifen
Yes (n=71) 61 58
No (n=33) 73 0.50 52 0.53
aOS=overall survival; DFS=disease-free survival.
bCR=complete response;
PR=partial response; SD=stable disease.
cCR: no residual tumour cells; Micro-
scopic/Macroscopic: microscopic/macroscopic residual disease.
dNumber of
involved nodes in the pathological specimen.
eIncluding neoadjuvant and adjuvant
CAF.
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Figure 3 Disease-free survival (A) and overall survival (B) by number of
metastatic axillary lymph nodes.
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cal response to neoadjuvant treatment (Robertson et al, 1994;
Walker et al, 1999) or local control (Pierce et al, 1992; Victor
et al, 1999). A thorough search of the literature revealed only a
few studies of LABC in which a formal prognostic factor analysis
was performed. Moreover, despite the diversity of outcome
measures used, we recognized only a few variables whose impact,
regardless of the manner of testing, was signiﬁcant. In a retro-
spective analysis of 100 patients, Victor et al (1999) correlated
the presence of IBC and four or more involved axillary nodes
with poorer outcome. Their conclusions were supported by
Gardin et al (1995) in an analysis of 125 patients, and by others
as well (Sanchez-Forgach et al, 1992; Kuerer et al, 1998; Zambetti
et al, 1999). The clinical size of the primary tumour (Valagussa et
al, 1990; Fein et al, 1994) as well as the clinical nodal status
(Valagussa et al, 1990) were also found to correlate with
outcome. Two studies identiﬁed the prognostic importance of
neoadjuvant treatment itself. Karlsson et al (1998) found that
worse OS and DFS were associated with the receipt of less than
75 and 60%, respectively, of the intended dose intensity. In a
phase II study, Honkoop et al (1998) noted a detrimental effect
of a lower number of preoperative chemotherapy cycles. Response
to preoperative treatment in LABC is a rather complex issue. In a
large prospective study, Kuerer et al (1998) found that achieve-
ment of a complete clinical response was associated with better
DFS. However, most authors agree that the pathological response
is more predictive of survival than the clinical response (Staloff et
al, 1995; Feldman et al, 1998; Honkoop et al, 1986). Many
aspects remain unclear in this regard. Is it solely the achievement
of a complete pathological response that distinguishes good from
bad prognosis, or does the favourable group also include patients
with residual microscopic disease? Is it the resolution of the
primary tumour that is most important or the extent of the
remaining axillary involvement, or both? Of the various histo-
pathological markers tested, only hormone-receptor positivity
(Robertson et al, 1994), co-expression of Pgp/p53 and marked
staining for Ki-67 (Honkoop et al, 1998) were found to inﬂuence
survival.
In conclusion, the present study identiﬁes four prognostic
factors of LABC: inﬂammatory features, number of involved nodes,
baseline tumour markers and nodal extracapsular spread. While the
prognostic importance of the ﬁrst two has already been established,
the inﬂuence of the latter two on overall and disease-free survival
of patients with LABC has not yet been fully acknowledged. As a
ﬁnding of extracapsular spread can inﬂuence the decision regarding
postoperative adjuvant treatment, the presence of elevated baseline
tumour markers may have a substantial impact on the preoperative
management too, provided these ﬁndings are supported by other
trials. In light of the generally disappointing results of current
therapies, patients manifesting any of these features should be
encouraged to participate in clinical trials.
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Figure 4 Disease-free survival (A) and overall survival (B) by extracap-
sular nodal spread.
Table 4 Overall survival: multivariate analysis
a
P value Risk ratio 95% CI
Clinical T 0.0000 9.0 3.4–23.7
Pathological nodal status 0.003 4.3 1.7–11.3
Baseline markers 0.003 4.2 1.6–11.1
Age 0.36 – –
Family history 0.06 – –
Clinical size 0.55 – –
Clinical nodal status 0.93 – –
Clinical response 0.11 – –
Pathological T 0.10 – –
Pathological residual disease 0.36 – –
Extracapsular spread 0.05 – –
Surgery 0.02 – –
aNumber of available patients=73; number of events=22. Overall score=33.722,
P=0.0000.
Table 5 Disease-free survival; multivariate analysis
a
P Risk ratio 95% CI
Clinical T 0.0004 4.6 2.0–10.7
Pathological nodal status 0.02 2.7 1.2–6.0
Baseline markers 0.003 3.4 1.5–7.6
Age 0.64 – –
Family history 0.10 – –
Clinical size 0.48 – –
Clinical nodal status 0.57 – –
Clinical response 0.29 – –
Pathological T 0.24 – –
Pathological residual disease 0.11 – –
Extracapsular spread 0.01 3.0 1.2–7.3
Surgery 0.61 – –
aNumber of available patients=73; number of events=30. Overall score=34.544,
P=0.0000.
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